Play Video
Neurological Diagnostics Innovation
Amoneta Diagnostics seeks, develops, and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
our neurodiagnostic proficiency
key figures
We specialize in neurodegenerative disease diagnostics, empowering healthcare professionals by providing vital insights to aid in informed medical decision-making.
explore our products
advanced precision medicine tools aiding specialists to make personalized medical decisions, drive progress in disease characterization, and identify potential therapeutic targets.
Amoneta announces the CE-marking under the EU-IVDR of its APO-Easy® Genotyping Kit.
From June 24 to 27, 2024, Amoneta's parent company Firalis hosted at its premises in Huningue a Summer School for the CombiDiag Do...
Amoneta Diagnostics' innovative diagnostic tools are now available on the MedicalExpo platform
Get in touch
Our partners
